Literature DB >> 3134628

Monitoring lupus anticoagulant-positive pregnancies with umbilical artery flow velocity waveforms.

B J Trudinger1, G J Stewart, C M Cook, A Connelly, T Exner.   

Abstract

The presence of the "lupus anticoagulant" in maternal blood is associated with thrombosis in the placental vessels and a high rate of fetal loss. We followed six pregnancies in four mothers positive for lupus anticoagulant autoantibody with Doppler umbilical flow studies. The women were not treated with any drugs, and clinical management was guided by close fetal surveillance including umbilical flow studies. Umbilical artery flow velocity waveforms detect vascular abnormalities in the fetal umbilical placental circulation and were used as an early indicator of developing disease. All pregnancies produced live-born infants. These cases indicate the potential value of such studies in the management of this group at high risk of fetal loss.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134628

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  5 in total

Review 1.  Pregnancy and antibodies to phospholipids.

Authors:  M J Walport
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

2.  Management of the antiphospholipid syndrome.

Authors:  M A Khamashta; T Wallington
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

Review 3.  Antiphospholipid antibodies. A marker for thrombosis and recurrent abortion.

Authors:  M A Khamashta; G R Hughes
Journal:  Clin Rev Allergy       Date:  1994

Review 4.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

5.  Thrombotic occlusion of an umbilical vein varix causing fetal death.

Authors:  H Schröcksnadel; E Holböck; G Mitterschiffthaler; M Tötsch; O Dapunt
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.